Search results
Results from the WOW.Com Content Network
Adenoid hypertrophy, also known as enlarged adenoids refers to an enlargement of the adenoid (pharyngeal tonsil) that is linked to nasopharyngeal mechanical blockage and/or chronic inflammation. [1] Adenoid hypertrophy is a characterized by hearing loss , recurrent otitis media , mucopurulent rhinorrhea , chronic mouth breathing , nasal airway ...
3D still showing adenoid hypertrophy. An enlarged adenoid, or adenoid hypertrophy, can become nearly the size of a ping pong ball and completely block airflow through the nasal passages. Even if the enlarged adenoid is not substantial enough to physically block the back of the nose, it can obstruct airflow enough so that breathing through the ...
The term pulmonary edema literally means wet lungs. This term actually refers to a pathological condition of the lungs, frequently demonstrated by chest X-ray. Edema of the lungs should be thought of as the result of a disease such as congestive heart failure and not a disease in and of itself. In this case it would be a cardiac disease and not ...
The tonsils are a set of lymphoid organs facing into the aerodigestive tract, which is known as Waldeyer's tonsillar ring and consists of the adenoid tonsil (or pharyngeal tonsil), two tubal tonsils, two palatine tonsils, and the lingual tonsils. These organs play an important role in the immune system.
lung injury of acute onset, within 1 week of an apparent clinical insult and with the progression of respiratory symptoms; bilateral opacities on chest imaging (chest radiograph or CT) not explained by other lung pathology (e.g. effusion, lobar/lung collapse, or nodules) respiratory failure not explained by heart failure or volume overload ...
Veronica Brown lived with chronic fatigue, depression, and anxiety for over 10 years before she learned they were early signs of Parkinson's disease. Here's how she found relief after diagnosis.
If you’re stuck on today’s Wordle answer, we’re here to help—but beware of spoilers for Wordle 1273 ahead. Let's start with a few hints.
Patients with left heart failure or hypoxemic lung diseases (groups II or III pulmonary hypertension) should not routinely be treated with vasoactive agents including prostanoids, phosphodiesterase inhibitors, or endothelin antagonists, as these are approved for the different condition called primary pulmonary arterial hypertension. [69]